<?xml version="1.0" encoding="UTF-8"?>
<p>In flavivirus seronegative adults, TV003/TV005 did however, elicit a near-sterilising immunity [
 <xref rid="B171-vaccines-07-00203" ref-type="bibr">171</xref>]. Nevertheless, the estimated date for study completion of these second-generation dengue vaccines are not expected until late 2021 and 2025 for TDV and TV003/TV005, respectively therefore the long-term effects are not yet known. A CD8 T-cell only vaccine would avoid antibody mediated disease enhancement, however they are currently none published, even though recent evidence suggests they could be highly protective [
 <xref rid="B106-vaccines-07-00203" ref-type="bibr">106</xref>,
 <xref rid="B111-vaccines-07-00203" ref-type="bibr">111</xref>,
 <xref rid="B137-vaccines-07-00203" ref-type="bibr">137</xref>].
</p>
